{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:44:26Z","timestamp":1774442666853,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1111\/jcpt.12561","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:59:29Z","timestamp":1495587569000},"page":"483-494","source":"Crossref","is-referenced-by-count":5,"title":["Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of\u00a0the\u00a0boxed warning"],"prefix":"10.1155","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8971-9748","authenticated-orcid":false,"given":"E.","family":"Eworuke","sequence":"first","affiliation":[{"name":"Division of Epidemiology II; Office of Pharmacovigilance and Epidemiology; Office of Surveillance and Epidemiology; Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Popat","sequence":"additional","affiliation":[{"name":"Office of New Drugs; Immediate Office; Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. G.","family":"Moeny","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II; Office of Pharmacovigilance and Epidemiology; Office of Surveillance and Epidemiology; Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"10.1111\/jcpt.12561-BIB0001|jcpt12561-cit-0001","unstructured":"Services USHaH Depo-Provera (NDA 020246) Label and Approval History Silver Spring U.S. Department of Health and Human Services"},{"key":"10.1111\/jcpt.12561-BIB0002|jcpt12561-cit-0002","unstructured":"Services USHaH Depo-Sub Q Provera (NDA 021583) Label and Approval History Silver Spring U.S. Department of Health and Human Services"},{"key":"10.1111\/jcpt.12561-BIB0003|jcpt12561-cit-0003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0015-0282(01)01748-4","article-title":"Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception","volume":"75","author":"Clark","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1111\/jcpt.12561-BIB0004|jcpt12561-cit-0004","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/01.AOG.0000117082.49490.d5","article-title":"Effects of hormonal contraception on bone mineral density after 24 months of use","volume":"103","author":"Berenson","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1111\/jcpt.12561-BIB0005|jcpt12561-cit-0005","first-page":"576","article-title":"A prospective, controlled study of the effects of hormonal contraception on bone mineral density","volume":"98","author":"Berenson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1111\/jcpt.12561-BIB0006|jcpt12561-cit-0006","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jadohealth.2006.03.011","article-title":"Depot medroxyprogesterone acetate and bone mineral density in adolescents-the Black Box Warning: a Position Paper of the Society for Adolescent Medicine","volume":"39","author":"Cromer","year":"2006","journal-title":"J Adolesc Health"},{"key":"10.1111\/jcpt.12561-BIB0007|jcpt12561-cit-0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1054-139X(02)00567-0","article-title":"Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years","volume":"32","author":"Busen","year":"2003","journal-title":"J Adolesc Health"},{"key":"10.1111\/jcpt.12561-BIB0008|jcpt12561-cit-0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpag.2003.11.017","article-title":"Bone mineral density in adolescent females using depot medroxyprogesterone acetate","volume":"17","author":"Lara-Torre","year":"2004","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1111\/jcpt.12561-BIB0009|jcpt12561-cit-0009","first-page":"736","article-title":"Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health","volume":"95","author":"Petitti","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1111\/jcpt.12561-BIB0010|jcpt12561-cit-0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpedi.159.2.139","article-title":"Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception","volume":"159","author":"Scholes","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1111\/jcpt.12561-BIB0011|jcpt12561-cit-0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.contraception.2003.10.005","article-title":"The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women","volume":"69","author":"Scholes","year":"2004","journal-title":"Contraception"},{"key":"10.1111\/jcpt.12561-BIB0012|jcpt12561-cit-0012","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.contraception.2008.07.022","article-title":"Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians","volume":"78","author":"Paschall","year":"2008","journal-title":"Contraception"},{"key":"10.1111\/jcpt.12561-BIB0013|jcpt12561-cit-0013","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.contraception.2011.01.009","article-title":"Removing the black box warning for depot medroxyprogesterone acetate","volume":"84","author":"Kaunitz","year":"2011","journal-title":"Contraception"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12561\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:02:48Z","timestamp":1671818568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12561","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}